A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

Bristol-Myers Squibb (BMS)

Status: Active, not recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Treatments: Drug: Mavacamten

Study type: Observational

Funder types: Industry

Identifiers

NCT07107373

CV027-1152

Details and patient eligibility

About

The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years at the index date
• Prescription of mavacamten for the treatment of Obstructive hypertrophic cardiomyopathy (oHCM) with NYHA Class II or III
• ≥ 12 weeks of follow-up after prescription of mavacamten, except for the baseline data reporting

Exclusion criteria

• Data collection as part of a clinical trial during the study period
• Participation in a myosin inhibitor clinical trial

Trial design

150 participants in 1 patient group

Participants receiving treatment mavacamten

Treatment:

Drug: Mavacamten